Beta-synuclein is a presynaptic neuronal protein encoded by the SNCB gene (synuclein beta), which is highly homologous to alpha-synuclein and belongs to the synuclein family of proteins [1]. While alpha-synuclein is well-known for its central role in Parkinson's disease pathogenesis as the major component of Lewy bodies, beta-synuclein has emerged as a significant regulatory protein that may influence disease progression through its ability to inhibit alpha-synuclein aggregation [2].
The synuclein family consists of three members: alpha-synuclein, beta-synuclein, and gamma-synuclein (SNCG). All three are small, acidic proteins expressed predominantly in neural tissue, particularly in presynaptic terminals. Beta-synuclein shares approximately 61% sequence homology with alpha-synuclein and is thought to have evolved from a common ancestral gene through gene duplication events.
:: infobox .infobox-protein
| Beta-Synuclein Protein | ||
|---|---|---|
| Gene | SNCB | |
| UniProt | P37840 | |
| Chromosomal Location | 5q35.2 | |
| Molecular Weight | ~14.5 kDa | |
| Amino Acids | 134 | |
| Protein Family | Synuclein family | |
| Aliases | SNCB, beta-syn |
===
Beta-synuclein is a 134-amino acid, intrinsically disordered protein with a molecular weight of approximately 14.5 kDa. The protein structure can be divided into three distinct domains:
The N-terminal region contains seven imperfect 11-amino acid repeats (KTKEGV) that share high homology with alpha-synuclein. These repeats are characteristic of the synuclein family and are thought to be involved in:
The NAC region of beta-synuclein is shorter than that of alpha-synuclein due to a deletion of five amino acids (positions 71-75). This shorter NAC region is believed to be crucial for the protein's reduced aggregation propensity compared to alpha-synuclein. The NAC region contains hydrophobic sequences that can form beta-sheet structures, but the deletion in beta-synuclein reduces its amyloidogenic potential.
The C-terminal domain is highly acidic (glutamate and aspartate-rich) and is thought to:
The key structural differences between beta-synuclein and alpha-synuclein include:
| Feature | Alpha-Synuclein | Beta-Synuclein |
|---|---|---|
| Amino acids | 140 | 134 |
| NAC region | Full (12 aa insert) | Shortened (5 aa deletion) |
| Aggregation propensity | High | Low |
| Presence in Lewy bodies | Yes | No |
| Phosphorylation sites | Multiple (Ser129) | Fewer |
The deletion in the NAC region of beta-synuclein is the primary structural feature that accounts for its dramatically reduced tendency to form amyloid fibrils compared to alpha-synuclein [3].
Beta-synuclein is abundantly expressed throughout the central nervous system, with highest levels in:
Expression is primarily localized to presynaptic terminals, where the protein is thought to play a role in synaptic function and plasticity [4].
Beta-synuclein exhibits several molecular functions in the normal brain:
Phospholipase D2 Inhibition: Beta-synuclein putatively inhibits phospholipase D2 (PLD2) activity, which may regulate membrane trafficking at synaptic terminals. This inhibition is selective for PLD2, as beta-synuclein does not significantly inhibit PLD1.
Calcium Ion Binding: The C-terminal acidic domain can bind calcium ions, suggesting a role in calcium homeostasis at presynaptic terminals. This calcium-binding capacity may be important for regulating neurotransmitter release.
Transition Metal Ion Binding: Beta-synuclein can bind copper and other transition metals, potentially protecting neurons from metal-induced oxidative stress.
Modulation of Neuronal Plasticity: Evidence suggests that beta-synuclein may play a role in neuronal plasticity, potentially through its effects on synaptic vesicle dynamics and membrane remodeling.
Synaptic Vesicle Regulation: As a presynaptic protein, beta-synuclein may regulate synaptic vesicle pool size, neurotransmitter release kinetics, and vesicle recycling.
While alpha-synuclein has been extensively studied for its role in synaptic vesicle regulation and as a molecular chaperone, the normal physiological functions of beta-synuclein are less well characterized. However, several lines of evidence suggest that:
Beta-synuclein has a complex and somewhat paradoxical relationship with Parkinson's disease:
Beta-synuclein is highly expressed in brain regions affected in PD, including the substantia nigra, striatum, and cortex. Studies have shown:
Unlike alpha-synuclein, beta-synuclein is not found in classic Lewy bodies. This fundamental difference has important implications:
Recent studies have demonstrated that beta-synuclein can aggregate in the brains of patients with advanced PD, forming cytoplasmic inclusions that are distinct from classical Lewy bodies [7]. These aggregates:
In dementia with Lewy bodies (DLB), beta-synuclein shows a characteristic pattern:
While not a primary feature of Alzheimer's disease, beta-synuclein has been implicated in AD pathogenesis:
One of the most significant findings about beta-synuclein is its ability to protect against alpha-synuclein-induced toxicity:
Multiple studies have demonstrated that beta-synuclein can inhibit alpha-synuclein aggregation through several mechanisms:
Animal studies have shown that beta-synuclein can protect against alpha-synuclein toxicity:
The neuroprotective effects of beta-synuclein appear to involve:
A polymorphism in the 3' untranslated region of the SNCB gene has been associated with susceptibility to Parkinson's disease in some populations [10]. This polymorphism may:
While mutations in the SNCA gene are well-established causes of familial PD, mutations in SNCB are rarer. However, rare variants have been identified in association with diffuse Lewy body disease [11], suggesting that:
Beta-synuclein levels in cerebrospinal fluid (CSF) have been investigated as a potential biomarker for Parkinson's disease:
The measurement of beta-synuclein in CSF shows promise for:
However, standardization of assays and validation in larger cohorts is needed before clinical implementation [13].
The neuroprotective properties of beta-synuclein make it an attractive therapeutic target:
Understanding the mechanisms by which beta-synuclein inhibits alpha-synuclein aggregation could lead to:
Beta-synuclein may protect neurons through antioxidant mechanisms [14]:
Biophysical studies have characterized the differences between alpha-synuclein and beta-synuclein aggregation:
Several key questions remain about beta-synuclein:
Uversky VN, Li J, Fink AL. The role of acidic proteins in neurodegeneration: alpha- and beta-synuclein. FEBS Lett. 2002. ↩︎
Hashimoto M, Rockenstein E, Mante M, et al. Beta-synuclein inhibits alpha-synuclein aggregation: a potential role in Parkinson's disease. Neuron. 2001. ↩︎
Tsvetkov AS, Arrasate M, Barmida S, et al. Beta-synuclein suppresses aggregation of alpha-synuclein at physiological concentrations. J Biol Chem. 2010. ↩︎ ↩︎
Nakamura K, Tsuji S, Tanaka J, et al. Cellular distribution of beta-synuclein in mouse brain. J Comp Neurol. 2018. ↩︎
Nakai T, Kitamura N, Hagiwara H, et al. beta-Synuclein is upregulated in neuronal degeneration. Acta Neuropathol. 2007. ↩︎
Parkkinen L, Kauppinen T, Pirttilä T, et al. beta-Synuclein aggregates in the olfactory bulb in Parkinson's disease. Acta Neuropathol. 2007. ↩︎
Meng T, Lin L, Liu Q, et al. Beta-synuclein aggregates in the brains of mice with advanced Parkinson's disease. J Neurochem. 2019. ↩︎
Quilty MC, Gai WP, Hgg ML, et al. beta-Synuclein in the hippocampus of patients with mild cognitive impairment. Exp Neurol. 2003. ↩︎
Perier C, Bencze J, Bové J, et al. beta-Synuclein promotes mitochondrial function and neuroprotection in PD models. Neurobiol Aging. 2017. ↩︎
Fan Y, Lim J, Ou JC, et al. Association of the 3'UTR polymorphism in the beta-synuclein gene with susceptibility to Parkinson's disease. J Neurol Sci. 2006. ↩︎
Iavaron E, Hu CA, Bai Y, et al. Beta-synuclein mutations associated with diffuse Lewy body disease. Mov Disord. 2021. ↩︎
Schell H, Hund A, Reck C, et al. beta-Synuclein levels in cerebrospinal fluid are altered in Parkinson's disease. J Neurol Neurosurg Psychiatry. 2012. ↩︎
Reck C, Marek M, Schell H, et al. beta-Synuclein in cerebrospinal fluid as a biomarker for Parkinson's disease. Neurology. 2021. ↩︎
Seet RC, Lee CY, Lim KH, et al. Oxidative modification of beta-synuclein and its implications in Parkinson's disease. Free Radic Biol Med. 2020. ↩︎